Kelemen LI - Search Results

1

Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis.

Jonsson JR, Clouston AD, Ando Y, Kelemen LI, Horn MJ, Adamson MD, Purdie DM, Powell EE. Jonsson JR, et al. Among authors: kelemen li. Gastroenterology. 2001 Jul;121(1):148-55. doi: 10.1053/gast.2001.25480. Gastroenterology. 2001. PMID: 11438504

2

Association between apolipoprotein E epsilon4 and neuropsychiatric symptoms during interferon alpha treatment for chronic hepatitis C.

Gochee PA, Powell EE, Purdie DM, Pandeya N, Kelemen L, Shorthouse C, Jonsson JR, Kelly B. Gochee PA, et al. Psychosomatics. 2004 Jan-Feb;45(1):49-57. doi: 10.1176/appi.psy.45.1.49. Psychosomatics. 2004. PMID: 14709760

3

RAD52 Y415X truncation polymorphism and epithelial ovarian cancer risk in Australian women.

Kelemen L, Spurdle AB, Purdie DM, Gertig D, Chenevix-Trench G. Kelemen L, et al. Cancer Lett. 2005 Feb 10;218(2):191-7. doi: 10.1016/j.canlet.2004.09.023. Cancer Lett. 2005. PMID: 15670896

4

The androgen receptor CAG repeat polymorphism and modification of breast cancer risk in BRCA1 and BRCA2 mutation carriers.

Spurdle AB, Antoniou AC, Duffy DL, Pandeya N, Kelemen L, Chen X, Peock S, Cook MR, Smith PL, Purdie DM, Newman B, Dite GS, Apicella C, Southey MC, Giles GG, Hopper JL, Chenevix-Trench G, Easton DF; EMBRACE Study Collaborators. Spurdle AB, et al. Breast Cancer Res. 2005;7(2):R176-83. doi: 10.1186/bcr971. Epub 2004 Dec 16. Breast Cancer Res. 2005. PMID: 15743497 Free PMC article.

5

Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancers.

Berchuck A, Schildkraut JM, Wenham RM, Calingaert B, Ali S, Henriott A, Halabi S, Rodriguez GC, Gertig D, Purdie DM, Kelemen L, Spurdle AB, Marks J, Chenevix-Trench G. Berchuck A, et al. Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2141-7. Cancer Epidemiol Biomarkers Prev. 2004. PMID: 15598772

6

BRAF polymorphisms and the risk of ovarian cancer of low malignant potential.

Kelemen L, James M, Spurdle A, Campbell I, Chang-Claude J, Peel D, Anton-Culver H, Berchuck A, Schildkraut J, Whittemore A, McGurie V, DiCioccio RA, Duffy D, Chenevix-Trench G. Kelemen L, et al. Gynecol Oncol. 2005 Jun;97(3):807-12. doi: 10.1016/j.ygyno.2005.03.007. Gynecol Oncol. 2005. PMID: 15904951

7

The AIB1 polyglutamine repeat does not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers.

Spurdle AB, Antoniou AC, Kelemen L, Holland H, Peock S, Cook MR, Smith PL, Greene MH, Simard J, Plourde M, Southey MC, Godwin AK, Beck J, Miron A, Daly MB, Santella RM, Hopper JL, John EM, Andrulis IL, Durocher F, Struewing JP, Easton DF, Chenevix-Trench G; Australian Breast Cancer Family Study; Australian Jewish Breast Cancer Study; Breast Cancer Family Registry; Interdisciplinary Health Research International Team on Breast Cancer Susceptibility; Kathleen Cunningham Foundation Consortium for Research into Familial Breast Cancer; Epidemiological Study of Familial Breast Cancer Study Collaborators. Spurdle AB, et al. Cancer Epidemiol Biomarkers Prev. 2006 Jan;15(1):76-9. doi: 10.1158/1055-9965.EPI-05-0709. Cancer Epidemiol Biomarkers Prev. 2006. PMID: 16434590

8

Further evidence for linkage of familial hyperaldosteronism type II at chromosome 7p22 in Italian as well as Australian and South American families.

Sukor N, Mulatero P, Gordon RD, So A, Duffy D, Bertello C, Kelemen L, Jeske Y, Veglio F, Stowasser M. Sukor N, et al. J Hypertens. 2008 Aug;26(8):1577-82. doi: 10.1097/HJH.0b013e3283028352. J Hypertens. 2008. PMID: 18622235

9

Polymorphisms associated with circulating sex hormone levels in postmenopausal women.

Dunning AM, Dowsett M, Healey CS, Tee L, Luben RN, Folkerd E, Novik KL, Kelemen L, Ogata S, Pharoah PD, Easton DF, Day NE, Ponder BA. Dunning AM, et al. J Natl Cancer Inst. 2004 Jun 16;96(12):936-45. doi: 10.1093/jnci/djh167. J Natl Cancer Inst. 2004. PMID: 15199113

10

No evidence for coding region mutations in the retinoblastoma-associated Kruppel-associated box protein gene (RBaK) causing familial hyperaldosteronism type II.

So A, Jeske YW, Gordon RD, Duffy D, Kelemen L, Stowasser M. So A, et al. Clin Endocrinol (Oxf). 2006 Dec;65(6):829-31. doi: 10.1111/j.1365-2265.2006.02674.x. Clin Endocrinol (Oxf). 2006. PMID: 17121540 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

13 results

Search Page